Literature DB >> 22326840

Current oral and non-oral routes of antiepileptic drug delivery.

Gail D Anderson1, Russell P Saneto.   

Abstract

Antiepileptic drugs are commonly given orally for chronic treatment of epilepsy. The treatment of epilepsy requires administration of medications for both acute and chronic treatment using multiple types of formulations. Parenteral routes are used when the oral route is unavailable or a rapid clinical response is required. Lorazepam and midazolam can be administered by the buccal, sublingual or intranasal routes. Consensus documents recommend rectal diazepam, buccal midazolam or intranasal midazolam for the out-of-hospital treatment of early status epilepticus. In the United States, diazepam is the only FDA approved rectal formulation. With the lack of parenteral, buccal or intranasal formulations for many of the antiepileptic drugs, the use of the rectal route of delivery to treat acute seizures or to maintain therapeutic concentrations is suitable for many, but not all antiepileptic medications. There is a significant need for new non-oral formulations of the antiepileptic drugs when oral administration is not possible.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22326840     DOI: 10.1016/j.addr.2012.01.017

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  17 in total

Review 1.  Pharmacokinetic of antiepileptic drugs in patients with hepatic or renal impairment.

Authors:  Gail D Anderson; Shahin Hakimian
Journal:  Clin Pharmacokinet       Date:  2014-01       Impact factor: 6.447

2.  Locomotor differences in Mongolian gerbils with the effects of midazolam administration in the form of eye drops.

Authors:  Akcan Akkaya; Umit Y Tekelioglu; Abdullah Demirhan; Mesut Erdurmus; Tayfun Apuhan; Hakan Bayir; Erol Ayaz; Hasan Kocoglu
Journal:  Afr Health Sci       Date:  2014-03       Impact factor: 0.927

Review 3.  The end-of-life phase of high-grade glioma patients: a systematic review.

Authors:  Eefje M Sizoo; H Roeline W Pasman; Linda Dirven; Christine Marosi; Wolfgang Grisold; Günther Stockhammer; Jonas Egeter; Robin Grant; Susan Chang; Jan J Heimans; Luc Deliens; Jaap C Reijneveld; Martin J B Taphoorn
Journal:  Support Care Cancer       Date:  2013-12-14       Impact factor: 3.603

Review 4.  Treatment of Generalized Convulsive Status Epilepticus in Pediatric Patients.

Authors:  Elizabeth L Alford; James W Wheless; Stephanie J Phelps
Journal:  J Pediatr Pharmacol Ther       Date:  2015 Jul-Aug

Review 5.  End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic literature review.

Authors:  Tobias Walbert; Muhib Khan
Journal:  J Neurooncol       Date:  2014-02-13       Impact factor: 4.130

6.  Perioperative care of a patient with neuronal ceroid lipofuscinoses.

Authors:  Hiromi Kako; David P Martin; Joseph D Tobias
Journal:  Saudi J Anaesth       Date:  2013-07

7.  Bimodal gastroretentive drug delivery systems of lamotrigine: formulation and evaluation.

Authors:  R R Poonuru; C S R Gonugunta
Journal:  Indian J Pharm Sci       Date:  2014 Nov-Dec       Impact factor: 0.975

8.  Formulation and optimization of polymeric nanoparticles for intranasal delivery of lorazepam using Box-Behnken design: in vitro and in vivo evaluation.

Authors:  Deepak Sharma; Dipika Maheshwari; Gilphy Philip; Ravish Rana; Shanu Bhatia; Manisha Singh; Reema Gabrani; Sanjeev K Sharma; Javed Ali; Rakesh Kumar Sharma; Shweta Dang
Journal:  Biomed Res Int       Date:  2014-07-14       Impact factor: 3.411

9.  Antiepileptic drug treatment in the end-of-life phase of glioma patients: a feasibility study.

Authors:  Johan A F Koekkoek; Tjeerd J Postma; Jan J Heimans; Jaap C Reijneveld; Martin J B Taphoorn
Journal:  Support Care Cancer       Date:  2015-09-25       Impact factor: 3.603

10.  Buccal midazolam for pediatric convulsive seizures: efficacy, safety, and patient acceptability.

Authors:  Mark Anderson
Journal:  Patient Prefer Adherence       Date:  2013-01-10       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.